PPTA Twitter

PlasmaProteins Primary immunodeficiencies (PI) are severe, chronic conditions that prevent immune systems from functioning properly. Each year, more than 130 #plasma donations are needed to treat just one person #LivingWithPI . bit.ly/2QF6N1B pic.twitter.com/FuDxI2jWOU
About 20 hours ago.
PlasmaProteins Looking for a #plasma donation center near you? There are more than 780 across the U.S. Use our locator tool to find the closest donation center: bit.ly/2oNjYBh pic.twitter.com/h9GIK9dVXQ
2 days ago.

2018 Plasma Protein Forum Highlights

Opening Session: Jan M. Bult, President and CEO of PPTA, opened the 2018 Plasma Protein Forum by welcoming attendees to Washington, DC. He then introduced the “How Is Your Day?” campaign to PPTA’s North America audience, highlighting the campaign’s goals and purpose. Mr. Bult acknowledged attendees living with rare diseases who have offered testimonials in support of the campaign – Tim Frost, Ed Burke, Chris Templin, and Terry Halper.

Chairman’s Welcome: David Bell, Chairman of the PPTA Global Board of Directors and Chief Innovation Officer, Grifols S.A., welcomed attendees and reiterated PPTA’s mission – to promote the availability of and access to safe and effective plasma protein therapeutics for all patients in the world. He then invited Jan M. Bult to the podium to receive PPTA’s Lifetime Achievement Award in recognition of his decades of service to PPTA and its industry members. Upon receiving the award, Mr. Bult noted his appreciation to the Global Board of Directors and offered gratitude to the entire PPTA staff for their work in support of PPTA’s mission.

Session One featured Anthony Castaldo (President, U.S. Hereditary Angioedema Association), Joanna Chorostowska-Wynimko, MD, PhD (Scientific Director, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland), and Professor Paolo Caraceni (Associate Professor, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy). Panelists provided their perspectives on the importance of access to care for patients who rely on plasma protein therapies to treat their diseases and the burden of disease each faces.

Session Two provided an opportunity for speakers to discuss issues related to regulatory initiatives focused on inspections and donor health. PPF attendees heard from – and asked questions of – Ginette Y. Michaud, M.D. (Director, Office of Biological Products Operations, U.S. Food & Drug Administration), Toby L. Simon, M.D. (Senior Medical Director, Plasma & Plasma Safety, CSL Plasma), and George B. Schreiber, Sc.D. (Director, Epidemiology, Plasma Protein Therapeutics Association).

Session Three addressed international access to plasma protein therapies. Professor Martin van Hagen, M.D., Ph.D. (Head, Clinical Immunology Unit Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands), opened the session by discussing whether personalized medicine is a national issue or if it is a cross-border, international focus area. Dr. Ranjeet S. Ajmani (CEO, PlasmaGen BioSciences PVt. Ltd.) and Antonio Condino-Neto, M.D., Ph.D. (President, Latin American Society for Immunodeficiencies) addressed challenges and opportunities to improving access to care in India and Brazil, respectively.

Dr. Otto Schwarz Award: David Bell, Chairman of the PPTA Global Board of Directors, presented the 2018 Dr. Otto Schwarz Award to Mr. Shinji Wada, Vice President, Japanese Affairs, Grifols S.A. The Dr. Otto Schwarz Award is presented only to those individuals whose efforts and commitment have significantly advanced the plasma protein therapeutics industry. PPTA congratulates Mr. Wada on this greatly deserved recognition.

Day One closed with a presentation from Dr. Alvin Roth, Ph.D., Craig and Susan McCaw Professor of Economics, Stanford University; George Gund Professor of Economics and Business Administration Emeritus, Harvard University; and 2012 recipient of the Nobel Memorial Prize in Economic Sciences. As a signatory to “Donation Ethics: Ethicists and Economists for Ethical Donation-Compensation Practices,” Dr. Roth argued strongly in favor of the ethics of compensation for plasma donation.

Day Two

Day Two of the Plasma Protein Forum began with an update on PPTA’s Source Division activities over the past year by Roger Brinser, Chairman of the PPTA Source Board of Directors and Director, Regulatory, BioLife Plasma Services/Shire. Mr. Brinser offered highlights from the Source Board of Directors and from PPTA committees whose efforts impact the collection of source plasma.

Session One focused on challenges impacting the collection of source plasma, including the perception of donor compensation and donor health. The session also included a discussion about plasma management in China. The session’s speakers were Nicola Lacetera, Ph.D. (Associate Professor, University of Toronto), Prof. Dr. Liu Zhong (Vice President, Institute of Blood Transfusion, Chinese Academy of Medical Sciences), and Chen Bin (Deputy Director, Medical Safety and Transfusion Division, Department of Medical Regulatory and Management, National Health Commission).

Session Two, the final session of the 2018 Plasma Protein Forum, focused on issues regarding national and global self-sufficiency and included comments from Bill Bees (Vice President, Plasma Technologies, Prometic Plasma Resources), Peter Jaworski, Ph.D. (Professor, Georgetown University), and Joshua Penrod, J.D., Ph.D. (Vice President, Source & International Affairs, PPTA).

See you June 18-19 in Reston, Virginia, for the 2019 Plasma Protein Forum!

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100